AstraZeneca: FDA approves inhaler for COPD
(CercleFinance.com) - The US Food and Drug Administration has approved an inhaler developed by AstraZeneca to treat chronic obstructive pulmonary disease, or COPD.
The device, Breztri Aerosphere, includes an inhaled corticosteroid with a long-acting muscarinic antagonist and a beta2-agonist delivered in a pressurised metered-dose system.
The inhaler, which has already been approved in Japan and China for patients with COPD, is currently under regulatory review in the EU.
Under the terms of a past deal to acquire Pearl Therapeutics, AstraZeneca will make a 150 million dollar milestone payment upon the regulatory approval of Breztri Aerosphere in the US.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The device, Breztri Aerosphere, includes an inhaled corticosteroid with a long-acting muscarinic antagonist and a beta2-agonist delivered in a pressurised metered-dose system.
The inhaler, which has already been approved in Japan and China for patients with COPD, is currently under regulatory review in the EU.
Under the terms of a past deal to acquire Pearl Therapeutics, AstraZeneca will make a 150 million dollar milestone payment upon the regulatory approval of Breztri Aerosphere in the US.
Copyright (c) 2020 CercleFinance.com. All rights reserved.